To view this email as a web page, click here.

JAVELIN Renal 101: Combination Therapy vs Standard of Care in Advanced RCC

Research presented at ASCO GU 2019 compared PFS with avelumab and axitinib vs sunitinib in patients with advanced renal cell carcinoma.
Read more

Bias for Patient-Reported Outcomes in Open-Label Cancer Trials: How Big of a Concern Is It?

The US Food and Drug Administration explored the possibility of such bias in a recent viewpoint published in JAMA Oncology.
Read more

IN CASE YOU MISSED IT

Risk of Future Cancers in Survivors of Childhood Hodgkin Lymphoma

Guidelines for cancer screening in survivors of childhood HL may be refined based on the results of this extended follow-up study, say the researchers.
Read more

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.